Essays on Government Policy and Pharmaceutical Innovation

Margaret E. Blume-Kohout

ResearchPublished Sep 23, 2009

New drug therapies may deliver many social and economic benefits, but current levels of innovation across diseases may not be socially optimal. This dissertation investigates two mechanisms by which governments may influence pharmaceutical research and development (R&D) priorities: (1) public funding for life sciences research; and (2) prescription drug insurance, as in Medicare Part D. The author finds federal funding for life sciences research spurs non-federal investment in academic R&D as well as downstream drug development. Likewise, introduction of Medicare Part D increased both the number of drugs entering clinical trials and firm R&D expenditures for higher-Medicare-share drugs.

Topics

Document Details

Citation

Chicago Manual of Style

Blume-Kohout, Margaret E., Essays on Government Policy and Pharmaceutical Innovation. Santa Monica, CA: RAND Corporation, 2009. https://www.rand.org/pubs/rgs_dissertations/RGSD248.html.
BibTeX RIS

Research conducted by

This publication is part of the RAND dissertation series. Dissertations are written by Ph.D. candidates at the RAND School of Public Policy and supervised, reviewed, and approved by a RAND School faculty committee overseeing each dissertation. The RAND School is the world's leading producer of Ph.D.'s in policy analysis.

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.